Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Key Takeaway: Precision BioSciences announced the grant of 39,146 restricted stock units (RSUs) to five new employees as part of its 2021 Employment Inducement Incentive Award Plan. This decision, approved by the Compensation Committee on November 16, 2026, aims to incentivize new hires to join the company. The RSUs will vest in equal installments over three years.

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences granted 39,146 RSUs to new employees.
  • Inducement awards aim to attract talent to the company.
  • The ARCUS platform is designed for effective gene editing.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+84%
120-day peak, hindsight
Typical move
10%
average across 14 past catalysts
Cash runway
~16 mo
Medium dilution risk
Lead asset
PBGENE-DMD
Phase 2 · Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD

Full Press Release Details

INVESTORS

DURHAM, N.C.--(BUSINESS WIRE)--Nov. 20, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that, on November 16, 2026, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan (“Inducement Award Plan”). The inducement awards consist of an aggregate total of 39,146 restricted stock units (“RSUs”), granted among five employees in connection with their commencement of employment. Each award was granted under Nasdaq Listing Rule 5635(c)(4) as an inducement for the employee to commence service with Precision.
The employees’ RSUs vest (subject to continued service to Precision through the applicable vesting dates) in substantially equal annual installments on each of the first three anniversaries of the date of the commencement of their employment.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. These features are intended for ARCUS nucleases to drive more defined therapeutic outcomes. Using ARCUS, the Company’s pipeline is comprised of clinical stage in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
The ARCUS® platform is being used to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination (removing a viral genome e.g. viral DNA such as in the Company’s PBGENE-HBV program), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single AAV such as in the Company’s PBGENE-DMD program) and gene insertion (inserting DNA into a gene to cause expression or add function).
View source version on businesswire.com: https://www.businesswire.com/news/home/20261120150585/en/

Investor and Media Contact: Naresh Tanna Chief Financial Officer Naresh.Tanna@precisionbiosciences.com

Source: Precision BioSciences, Inc.

Investors

• Events & Presentations
• Press Releases
• Corporate Deck
• Stock Information
• Analyst Coverage
• SEC Filings
• Corporate Governance
• Sustainability
• Investor FAQs

Investor Tools

Frequently Asked Questions

What are the inducement awards granted by Precision BioSciences?

Precision BioSciences granted 39,146 RSUs to five new employees.

What is the purpose of the inducement awards?

The awards aim to incentivize new hires to join the company.

When were the inducement awards approved?

The awards were approved on November 16, 2026.

How do the RSUs vest?

The RSUs vest in equal installments over three years.

Last updated: Nov 20, 2026